-+ 0.00%
-+ 0.00%
-+ 0.00%
Crism Therapeutics Treats First Patient in Mid-stage Glioblastoma Trial
Share
Listen to the news
04:26 AM EST, 11/17/2026 (MT Newswires) -- Crism Therapeutics (CRTX.L) treated the first patient in its phase 2 clinical trial to treat glioblastoma patients with its irinotecan ChemoSeed implant. The UK clinical-stage drug delivery company said Tuesday that its study, which was conducted at the University Hospitals Birmingham NHS Foundation Trust, reported that the patient was clinically stable after the initial operations. The company added that the patient will now undergo post-operative clinical and imaging evaluations for the next steps of the trial.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending